Print Page   |   Sign In   |   Create a Profile
News & Press: Industry News

Axion wins SLAS New Product Award for Lumos and Maestro APEX

Monday, February 8, 2016   (0 Comments)
Posted by: Angela King
Share |

Atlanta, GA – February 8, 2016 – Axion BioSystems, developer of the Maestro™ microelectrode array (MEA) platform, is pleased to announce designation as a New Product Award winner at the recent Society for Laboratory Automation and Screening annual meeting (SLAS2016) in San Diego, California.    Two Axion products, Lumos™ high-throughput optical stimulation device, and Maestro APEX™ the industry’s first robotic platform for automation of all facets of MEA assay preparation and execution, competed against 40 product submissions. Together, they earned best in show based on market opportunity, impact, originality and proof of concept.

“Lumos represents the marriage of two powerful techniques,” said Jim Ross, PhD, Axion Chief Technology Officer.  “Functional activity assays on the Maestro MEA platform and optogenetics – artifact-free optical cellular control through the use of light-sensitive opsins.  Researchers now have unprecedented control over cellular behavior while recording real-time responses of neural and cardiomyocyte networks.  Each of 48 wells can be independently and simultaneously controlled, a true advancement in the in vitro optogenetics field.

“Our team is also responsible for Maestro APEX, the first robotic platform designed to automate and standardize the preparation, maintenance, and execution of MEA plates.  We partnered with laboratory automation leader Hamilton Robotics to build an automated platform around the Maestro system and paired it with an environmentally controlled incubator enabling greater throughput, enhanced accuracy, and true walk-away capability.  This integrated platform makes Maestro APEX an ideal tool to address upcoming requirements of the Food and Drug Administration’s Comprehensive in vitro Pro-Arrhythmia (CiPA) initiative”.

Axion President and CEO, Thomas O’Brien, said, “We have an immensely talented team in all facets of our organization.  One of our company’s missions is to bring innovative, easy-to-use products to the scientific community thereby enabling greater discoveries.  Although these products were recently introduced, both have already been adopted for use in Safety Pharmacology, Drug Discovery and basic research.  Now, to be recognized by our peers for doing just that is quite an honor”.

About Axion BioSystems

Axion BioSystems is the leader in microelectrode array (MEA) data acquisition and analysis.  With the Maestro MEA platform, functional activity assays on neural or cardiomyocyte cell networks are easily performed on the benchtop facilitating investigations in neurotoxicology, cardiac safety, in vitro disease modeling, and drug discovery.  Scalability options from 12- to 96-wells meets high throughput screening needs as well as assay development and follow-up studies – all using a single system.    To learn more about microelectrode array technology and applications, including Lumos and Maestro APEX, please visit

Catherine Parrish
Product Marketing Manager

Source: Axion Biosystems.

more Calendar

Boehringer-Ingelheim Industry Tour

Member Benefits Webinar

Membership Software Powered by YourMembership  ::  Legal